(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Astronauts' brains change shape and position after time in space, study finds - 2'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 3Dad issues urgent plea to find stem cell donor for his son
- 4A definitive Manual for the 5 Off-road Bicycles Available
- 5Spain and Catholic Church agree to compensate sex abuse victims
- Vote in favor of Your Number one kind of pie
- vote in favor of Your #1 kind of climate
- 10 Demonstrated Systems to Develop Your Internet based Business
- CDC changes kids' vaccine schedule, removing universal recommendation for some shots
- New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- BHP liable for 2015 Brazil mine disaster: UK court
- Protester climbs on to balcony of Iranian embassy in London
- A NASA spacecraft orbiting Mars may be dead
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
